Glenmark Pharmaceuticals’ US arm launches Lacosamide Oral Solution

16 Dec 2024 Evaluate

Glenmark Pharmaceuticals’ US-based subsidiary -- Glenmark Pharmaceuticals Inc, has launched Lacosamide Oral Solution, 10 mg/mL. Glenmark’s Lacosamide Oral Solution, 10 mg/mL is bioequivalent and therapeutically equivalent to the reference listed drug, Vimpat Oral Solution, 10 mg/mL of UCB, Inc. According to IQVIA sales data for the 12-month period ending October 2024, the Vimpat Oral Solution, 10 mg/mL market achieved annual sales of around $57.0 million.

Glenmark’s current portfolio includes 201 products authorized for distribution in the U.S. marketplace and 51 ANDA’s pending approval with the USFDA. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to further enhance and accelerate the growth of its existing pipeline and portfolio.

Glenmark Pharmaceuticals is a global research-led pharmaceutical company with presence across Generics, Specialty and OTC business with operations in over 50 countries. 

Glenmark Pharma Share Price

1524.20 11.60 (0.77%)
18-Dec-2024 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1800.30
Dr. Reddys Lab 1275.05
Cipla 1472.05
Lupin 2098.70
Zydus Lifesciences 979.10
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.